Editors' Note: This article covers stocks trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.
Tonix Pharmaceuticals (NASDAQ:TNXP), which is developing a sublingual formulation of cyclobenzaprine known as TNX-102 SL for use in fibromyalgia and post-traumatic stress disorder, has enjoyed a powerful rally (partially catalyzed by an outstanding article by Joe Springer) with the stock rising from $8.50 to a peak of $21 in the past month. The entire investment thesis on TNXP lies in whether the pivotal phase 2b trial expecting results in October 2014 will succeed. In this article, I provide a digest of the medical literature relevant...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|